Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study

Gynecologic Oncology

Volumn 121, Issue 2, 2011, Pages 395-401

  Farley, John ^a   Smith, Leia M ^b   Darcy, Kathleen M ^c   Brady, Mark F ^c   Bell, Jeffrey ^d   McGuire, William ^e   Birrer, Michael J ^f,g,h  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b SEATTLE GENETICS INC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d RIVERSIDE METHODIST HOSPITAL   (United States)

^e Franklin Square Hospital Center   (United States)

^f Cancer Center   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinogenesis; Immunohistochemistry; Ovary; p27; Prognostic

Indexed keywords

CYCLIN E; PROTEIN P27;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE;

AGED; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 79955477541     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.023     Document Type: Article

References (39)

1. Young R.P. Cancer of the ovary 4th ed. 1993 Lippincott Philadelphia
2. A. Jemal, S. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. A. Kamb Cell-cycle regulators and cancer Trends Genet 11 1995 136 140
4. T. Hunter, and J. Pines Cyclins and cancer II: cyclin D and CDK inhibitors come of age Cell 79 1994 573 582 (Pubitemid 24363801)
5. H. Toyoshima, and T. Hunter p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 78 1994 67 74 (Pubitemid 24228301)
6. C. Craig, R. Wersto, M. Kim, E. Ohri, Z. Li, and D. Katayose A recombinant adenovirus expressing p27 Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells Oncogene 14 1997 2283 2289 (Pubitemid 27260720)
7. S.S. Millard, J.S. Yan, H. Nguyen, M. Pagano, H. Kiyokawa, and A. Koff Enhanced ribosomal association of p27 (Kip1) mRNA is a mechanism contributing to accumulation during growth arrest J Biol Chem 272 1997 7093 7098 (Pubitemid 27166413)
8. K. Polyak, M.H. Lee, H. Erdjument-Bromage, A. Koff, J.M. Roberts, and P. Tempst Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals Cell 78 1994 59 66
9. M.V. Ponce-Castaneda, M.H. Lee, E. Latres, K. Polyak, L. Lacombe, and K. Montgomery p27 Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors Cancer Res 55 1995 1211 1214
10. K.S. Spirin, J.F. Simpson, S. Takeuchi, N. Kawamata, C.W. Miller, and H.P. Koeffler p27/ Kip1 mutation found in breast cancer Cancer Res 56 1996 2400 2404 (Pubitemid 26154089)
11. R.J. Sheaff, M. Groudine, M. Gordon, J.M. Roberts, and B.E. Clurman Cyclin E-CDK2 is a regulator of p27Kip1 Genes Dev 11 1997 1464 1478
12. H.C. Drexler Activation of the cell death program by inhibition of proteasome function Proc Natl Acad Sci USA 94 1997 855 860 (Pubitemid 27074411)
13. M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, and V. Chau Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 269 1995 682 685
14. M. Loda, B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, and G.F. Draetta Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nat Med 3 1997 231 234 (Pubitemid 27064711)
15. B.L. Harvat, P. Seth, and A.M. Jetten The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells Oncogene 14 1997 2111 2122 (Pubitemid 27237014)
16. P.L. Porter, K.E. Malone, P.J. Heagerty, G.M. Alexander, Gatti La, and E.J. Firpo Expression of cell-cycle regulators p27 Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nat Med 3 1997 222 225 (Pubitemid 27064709)
17. C. Catzavelos, N. Bhattacharya, Y.C. Ung, J.A. Wilson, L. Roncari, and C. Sandhu Decreased levels of the cell-cycle inhibitor p27Kip 1 protein: prognostic implications in primary breast cancer Nat Med 3 1997 227 230 (Pubitemid 27064710)
18. L. Sui, Y. Dong, M. Ohno, K. Sugimoto, Y. Tai, and T. Hando Implication of malignancy and prognosis of p27 (kip1), cyclin E, and Cdk2 expression in epithelial ovarian tumors Gynecol Oncol 83 2001 56 63 (Pubitemid 32959879)
19. L. Sui, M. Tokuda, M. Ohno, O. Hatase, and T. Hando The concurrent expression of p27 (kip1) and cyclin D1 in epithelial ovarian tumors Gynecol Oncol 73 1999 202 209 (Pubitemid 29215732)
20. E. Rosenberg, R.I. Demopoulos, A. Zeleniuch-Jacquotte, H. Yee, J. Sorich, and J.L. Speyer Expression of cell cycle regulators p57 (KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival Hum Pathol 32 2001 808 813 (Pubitemid 32803981)
21. M.G. Teneriello, M. Ebina, R.I. Linnoila, M. Henry, J.D. Nash, and R.C. Park p53 and Ki-ras gene mutations in epithelial ovarian neoplasms Cancer Res 53 1993 3103 3108 (Pubitemid 23210320)
22. Bell J., Brady M., Lage J., Look K.Y., Spirtos N., and Walker J. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2003 156 (abstract)
23. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
24. J. Farley, L.M. Smith, K.M. Darcy, E. Sobel, D. O'Connor, and B. Henderson Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study Cancer Res 63 2003 1235 1241 (Pubitemid 36348700)
25. A. Agresti A survey of exact inference for contingency tables Stat Sci 7 1992 131 177
26. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
27. M.S. Pepe, and M. Mori Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12 1993 737 751 (Pubitemid 23134304)
28. D.R. Cox Regression models and life tables J R Stat Soc 34 1972 187 220
29. Therneau T.M., and Grambsch P.M. Modeling survival data: extending the Cox model 2000 Springer-Verlag New York
30. S. Fredersdorf, J. Burns, A.M. Milne, G. Packham, L. Fallis, and C.E. Gillett High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers Proc Natl Acad Sci USA 94 1997 6380 6385
31. R.V. Lloyd, L. Jin, X. Qian, and E. Kulig Aberrant p27 kip1 expression in endocrine and other tumors Am J Pathol 150 1997 401 407 (Pubitemid 27073769)
32. V. Masciullo, G. Ferrandina, B. Pucci, F. Fanfani, S. Lovergine, and J. Palazzo p27 Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis Clin Cancer Res 6 2000 4816 4822 (Pubitemid 32110425)
33. G. Orend, T. Hunter, and E. Ruoslahti Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21 Kip1 and p27 Kip1 in anchorage-independent cells Oncogene 16 1998 2575 2583 (Pubitemid 28264035)
34. A. Loubat, N. Rochet, L. Turchi, R. Rezzonico, D.F. Far, and P. Auberger Evidence for a p23 caspase-cleaved form of p27 [KIP1] involved in G1 growth arrest Oncogene 18 1999 3324 3333 (Pubitemid 29286978)
35. M. Baekelandt, R. Holm, C.G. Tropé, J.M. Nesland, and G.B. Kristensen Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study Clin Cancer Res 5 1999 2848 2853 (Pubitemid 29493962)
36. D.G. Rosen, G. Yang, K.Q. Cai, R.C. Bast Jr., D.M. Gershenson, and E.G. Silva Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer Clin Cancer Res 11 2005 632 637 (Pubitemid 40116889)
37. A. Psyrri, A. Bamias, Z. Yu, P.M. Weinberger, M. Kassar, and S. Markakis Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer Clin Cancer Res 11 2005 8384 8390 (Pubitemid 41746951)
38. T. Soucek, R.S. Yeung, and M. Hengstschläger Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2 Proc Natl Acad Sci USA 95 1998 15653 15658 (Pubitemid 29018755)
39. V. Masciullo, A. Sgambato, C. Pacilio, B. Pucci, G. Ferrandina, and J. Palazzo Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer Cancer Res 59 1999 3790 3794 (Pubitemid 29381888)